Skip to main content Accessibility help
  • Print publication year: 2011
  • Online publication date: August 2011

7 - Dementia and parkinsonism


1. McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113–24.
2. McKeith IG, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863–72.
3. Lippa CF, Duda JE, Grossman M et al. DLB and PDD boundary issues – diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812–19.
4. Fujishiro H, Ferman TJ, Boeve BF et al. Validation of the neuropathologic criteria of the Third Consortium for Dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol 2008; 67: 649–56.
5. Merdes AR, Hansen LA, Jeste DV et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60: 1586–90.
6. Braak H, Del Tredici K, Rub U, de Vos RAI, Steur ENHJ, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197–211.
7. Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm 2004; 111: 1219–35.
8. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007; 27: 1405–10.
9. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005; 34: 561–6.
10. Matsui Y, Tanizaki Y, Arima H et al. Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. J Neurol Neurosurg Psychiatry 2009; 80: 366–70.
11. Zarranz JJ, Alegre J, Gomez-Esteban JC et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164–73.
12. Zimprich A, Biskup S, Leitner P et al. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601–7.
13. Clark LN, Kartsaklis LA, Gilbert RW et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009; 66: 578–83.
14. Borroni B, Grassi M, Costanzi C, Archetti S, Caimi L, Padovani A. APOE genotype and cholesterol levels in Lewy body dementia and Alzheimer disease: investigating genotype-phenotype effect on disease risk. Am J Geriatr Psychiatry 2006; 14: 1022–31.
15. Kraybill ML, Larson EB, Tsuang DW et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005; 64: 2069–73.
16. Nelson PT, Kryscio RJ, Jicha GA et al. Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology 2009; 73: 1127–33.
17. Bradshaw J, Saling M, Hopwood M, Anderson V, Brodtmann A. Fluctuating cognition in dementia with Lewy bodies and Alzheimer’s disease is qualitatively distinct. J Neurol Neurosurg Psychiatry 2004; 75: 382–7.
18. Ferman TJ, Smith GE, Boeve BF et al. DLB fluctuations – Specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004; 62: 181–7.
19. Walker MP, Ayre GA, Cummings JL et al. Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology 2000; 54: 1616–24.
20. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391–403.
21. Burn DJ, Rowan EN, Allan LM, Molloy S, T O’Brien J, McKeith IG. Motor subtype and cognitive decline in Parkinson’s disease, Parkinson’s disease with dementia, and dementia with Lewy bodies. Journal of Neurology Neurosurgery and Psychiatry 2006; 77: 585–9.
22. Louis ED, Klatka LA, Liu Y, Fahn S. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson’s disease. Neurology 1997; 48: 376–80.
23. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology 2009; 73: 206–12.
24. Ballard CG, Shaw F, Lowery K, McKeith I, Kenny R. The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer’s disease. Dement Geriatr Cogn Disord 1999; 10: 97–103.
25. Gnanalingham KK, Byrne EJ, Thornton A, Sambrook MA, Bannister P. Motor and cognitive function in lewy body dementia: comparison with Alzheimer’s and Parkinson’s diseases. J Neurol Neurosurg Psychiatry 1997; 62: 243–52.
26. Aarsland D, Perry R, Larsen JP et al. Neuroleptic sensitivity in Parkinson’s disease and parkinsonian dementias. J Clin Psychiatry 2005; 66: 633–7.
27. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord 2001; 16: 622–30.
28. Braak H, Rub U, Sandmann-Keil D et al. Parkinson’s disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol 2000; 99: 489–95.
29. Allan LM, Ballard CG, Allen J et al. Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry 2007; 78: 671–7.
30. Ransmayr GN, Holliger S, Schletterer K et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology 2008; 70: 299–303.
31. McKeith I, O’Brien J, Walker Z et al. Sensitivity and specificity of dopamine transporter imaging with I-123-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007; 6: 305–13.
32. Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, Kuhl DE. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001; 50: 358–65.
33. Lobotesis K, Fenwick JD, Phipps A et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001; 56: 643–9.
34. Gomperts SN, Rentz DM, Moran E et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71: 903–10.
35. Barber R, Ballard C, McKeith IG, Gholkar A, O’Brien JT. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology 2000; 54: 1304–9.
36. Estorch M, Camacho V, Paredes P et al. Cardiac I-123-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging 2008; 35: 1636–41.
37. Molloy S, McKeith IG, O’Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005; 76: 1200–3.
38. Alty JE, Clissold BG, McColl CD, Reardon KA, Shiff M, Kempster PA. Longitudinal study of the levodopa motor response in Parkinson’s disease: relationship between cognitive decline and motor function. Mov Disord 2009; 24: 2337–43.
39. Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008; 23: 2248–50.
40. Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351: 2509–18.
41. McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031–6.
42. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002; 72: 708–12.
43. Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934–9.
44. Miyasaki JM, Shannon K, Voon V et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review) – Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 996–1002.
45. Burn D, Emre M, McKeith I et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 2006; 21: 1899–907.
46. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical Antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225–35.
47. Kurlan R, Cummings J, Raman R, Thal L, Alzheimer’s Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007; 68: 1356–63.
48. Friedman J, Lannon M, Comella C et al. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med 1999; 340: 757–63.
49. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson’s disease versus dementia with Lewy bodies. J Clin Psychiatry 2002; 63: 513–5.
50. Lapierre O, Montplaisir J. Polysomnographic features of REM-sleep behavior disorder: development of a scoring method. Neurology 1992; 42: 1371–4.
51. Shannon JR, Jordan J, Grogan E et al. The pressor response to water drinking in humans: a sympathetic reflex? Circulation 1998; 98: 2484.
52. Bouvette CM, McPhee BR, OpferGehrking TL, Low PA. Role of physical countermaneuvers in the management of orthostatic hypotension: efficacy and biofeedback augmentation. Mayo Clin Proc 1996; 71: 847–53.